ILiAD Biotechnologies secures $115M in an oversubscribed Series B financing led by RA Capital Management for the advancement of its BPZE1 pertussis vaccine.
PRIVATEFeb 10, 2026
Amount Raised
$115 Million
Round Type
Series B
WestonBiotechnology
Investors
Janus Henderson InvestorsBNP Paribas Asset Management AltsRa Capital Management
Description
ILiAD Biotechnologies announced the successful closing of an oversubscribed $115 million Series B financing. Led by RA Capital Management, the funding will support the advancement of ILiAD's next generation pertussis vaccine candidate, BPZE1. This financing also saw participation from Janus Henderson Investors and BNP Paribas Asset Management Alts. The company expects to begin a pivotal human challenge trial of BPZE1 in 2026.
Company Information
Company
ILiAD Biotechnologies
Location
4581 Weston Road, Suite 260
Weston, Florida, United States
About
ILiAD Biotechnologies is a [Phase 3 ready] clinical-stage biotech company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis and other respiratory diseases.
Fundz sees it the moment ILiAD Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WestonBiotechnology